To increase the efficiency of the reaction and reduce the risk of the formation of nonspecific products before the start of the reaction, the reagent kit provides a “hot” start.

The kit contains a protection system that allows you to avoid contamination of the PCR mixture with amplicons (products of previous reactions) and obtaining false positive results, through the use of the enzyme uracil-DNA glycosylase (UDG) and deoxyuridine triphosphate (dUTP).

The use of simple and identical protocols significantly reduces the risk of operator error at all stages of work.

Using a simple and fast amplification protocol, which allows you to obtain reliable research results in 80 minutes, which significantly increases the flow of laboratory tests.

The presence of endogenous control is recorded via the Hex fluorescence channel. The use of internal control allows not only to control all stages of the PCR study for each sample, but also to assess the adequacy of the collection of biomaterial and its storage.

A simple interpretation of the results: the presence of a fluorescent signal through the Fam channel registers the presence of the HLA-B27 alley, both in a homozygous and heterozygous state, in a biological sample.

Possibility of using various types of amplifiers with detection of results in “real time” mode. For example: tablet type – “DTprime”, “DTlight”, “DT-96” (DNK-Technology LLC, Russia), or CFX96 (Bio-Rad Laboratories, USA), qTOWER 3 (Analytik Jena, Germany), Gentier 96E/ 96T/96R (Tianlong, China), rotary-type detecting amplifier, for example, Rotor-Gene 6000, Rotor-Gene Q (QIAGEN, Germany) and similar devices with the appropriate technical parameters.

To increase the efficiency of the reaction and reduce the risk of the formation of nonspecific products before the start of the reaction, the reagent kit provides a “hot” start.

The kit contains a protection system that allows you to avoid contamination of the PCR mixture with amplicons (products of previous reactions) and obtaining false positive results, through the use of the enzyme uracil-DNA glycosylase (UDG) and deoxyuridine triphosphate (dUTP).
The use of simple and identical protocols significantly reduces the risk of operator error at all stages of work.

Using a simple and fast amplification protocol, which allows you to obtain reliable research results in 80 minutes, which significantly increases the flow of laboratory tests.

The presence of endogenous control is recorded via the Fam fluorescence channel. The use of internal control allows not only to control all stages of the PCR study for each sample, but also to assess the adequacy of the collection of biomaterial and its storage.

A simple interpretation of the results: the absence of a fluorescent signal through the Hex channel registers the presence of a homozygous deletion of exon 7 in the SMN1 gene.

Possibility of using various types of amplifiers with detection of results in “real time” mode. For example: tablet type – “DTprime”, “DTlight”, “DT-96” (DNK-Technology LLC, Russia), or CFX96 (Bio-Rad Laboratories, USA), qTOWER 3 (Analytik Jena, Germany), Gentier 96E/ 96T/96R (Tianlong, China), rotary-type detecting amplifier, for example, Rotor-Gene 6000, Rotor-Gene Q (QIAGEN, Germany) and similar devices with the appropriate technical parameters.

To increase the efficiency of the reaction and reduce the risk of the formation of nonspecific products before the start of the reaction, the reagent kit provides a “hot” start.

The kit contains a protection system that allows you to avoid contamination of the PCR mixture with amplicons (products of previous reactions) and obtaining false positive results, through the use of the enzyme uracil-DNA glycosylase (UDG) and deoxyuridine triphosphate (dUTP).
The use of simple and identical protocols significantly reduces the risk of operator error at all stages of work.

Using a simple and fast amplification protocol, which allows you to obtain reliable research results in 80 minutes, which significantly increases the flow of laboratory tests.

The presence of endogenous control is recorded via the Fam fluorescence channel. The use of internal control allows not only to control all stages of the PCR study for each sample, but also to assess the adequacy of the collection of biomaterial and its storage.

A simple interpretation of the results: the absence of a fluorescent signal through the Cy5 channel registers the presence of a homozygous deletion of exon 7 in the SMN1 gene. Quantitative DNA analysis of TREC and KREC is performed using software.

Possibility of using various types of amplifiers with detection of results in “real time” mode. For example: tablet type – “DTprime”, “DTlight”, “DT-96” (DNK-Technology LLC, Russia), or CFX96 (Bio-Rad Laboratories, USA), qTOWER 3 (Analytik Jena, Germany), Gentier 96E/ 96T/96R (Tianlong, China), rotary-type detecting amplifier, for example, Rotor-Gene 6000, Rotor-Gene Q (QIAGEN, Germany) and similar devices with the appropriate technical parameters.

An innovative breakthrough in the medical and biotechnological field of Uzbekistan: the ROSSA company became the first manufacturer in the country to develop and register “ROSSAmed PID” kit for the quantitative detection of T- and B-cell receptor DNA ring structures (TREC and KREC) using the polymerase chain reaction method in real mode time.

This unique set of reagents allows you to accurately and quickly diagnose primary immunodeficiency conditions (PIDS), as well as monitor the effectiveness of therapy through the quantitative analysis of DNA circular structures specific to T and B cells.

The kit is based on advanced molecular and genetic technologies allowing quantitative analysis of TREC and KREC with high accuracy and sensitivity. The kit has been clinically tested to demonstrate functionality and reliability, making it suitable for widespread use in clinical practice.

Following the successful launch of production, reagent kits for the quantitative detection of TREC and KREC will be available in medical institutions throughout the country, significantly improving the quality and accuracy of diagnosis of immunodeficiencies. The ROSSA company is also considering the possibility of entering international markets, which will strengthen Uzbekistan’s position as a center of high-tech medical innovation.

To increase the efficiency of the reaction and reduce the risk of the formation of nonspecific products before the start of the reaction, the reagent kit provides a “hot” start.

The kit contains a protection system that allows you to avoid contamination of the PCR mixture with amplicons (products of previous reactions) and obtaining false positive results, through the use of the enzyme uracil-DNA glycosylase (UDG) and deoxyuridine triphosphate (dUTP).

The use of simple and identical protocols significantly reduces the risk of operator error at all stages of work.

Using a simple and fast amplification protocol, which allows you to obtain reliable research results in 80 minutes, which significantly increases the flow of laboratory tests.

The presence of endogenous control is recorded via the Fam fluorescence channel. The use of internal control allows not only to control all stages of the PCR study for each sample, but also to assess the adequacy of the collection of biomaterial and its storage.

Easy interpretation of results: Quantitative DNA analysis is carried out using software.

Possibility of using various types of amplifiers with detection of results in “real time” mode. For example: tablet type – “DTprime”, “DTlight”, “DT-96” (DNK-Technology LLC, Russia), or CFX96 (Bio-Rad Laboratories, USA), qTOWER 3 (Analytik Jena, Germany), Gentier 96E/ 96T/96R (Tianlong, China), rotary-type detecting amplifier, for example, Rotor-Gene 6000, Rotor-Gene Q (QIAGEN, Germany) and similar devices with the appropriate technical parameters.

ROSSA is proud to announce announces admission to the second stage of registration of PCR kits(“ROSSAmed HBV/HCV/HIV-1″,”ROSSAmed HIV-quant”, “ROSSAmed HBV-DNA-quant”, “ROSSAmed HCV-quant”, MagSorb Plasma isolation systems) on the territory of the Russian Federation. This important step marks a significant achievement in expanding the company’s presence in international markets and confirms the high quality of ROSSA products.

Registration of medical devices, in particular reagents for laboratory research, in Russia takes place in several stages and includes thorough verification, clinical trials and assessment of product compliance with international quality and safety standards. Successful completion of the first stage indicates that ROSSA reagents meet the strict requirements imposed by Russian regulators. To date, clinical trials of the products have begun.

The obtained clinical trial results reinforce the company’s reputation as a reliable manufacturer of diagnostic kits and contribute to building trust among consumers and partners.

This important achievement supports ROSSA’s strategic vision of improving the quality of diagnosis and treatment of diseases, as well as confirms Uzbekistan’s capabilities in the field of biotechnological innovations and the production of high-end medical devices.